Walleye Capital’s Altimmune ALT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$33.5K Buy
+11,700
New +$35.9K ﹤0.01% 5558
2026
Q2
– Sell
-800
Closed -$2.46K – 4698
2026
Q1
$2.46K Sell
800
-2,700
-77% -$11.5K ﹤0.01% 4228
2025
Q4
$12.6K Buy
3,500
+3,300
+1,650% +$14.4K ﹤0.01% 4287
2025
Q3
$754 Sell
200
-8,800
-98% -$34K ﹤0.01% 4383
2025
Q2
$34.8K Buy
+9,000
New +$48.7K ﹤0.01% 4132
2025
Q1
– Sell
-8,400
Closed -$60.6K – 4194
2024
Q4
$60.6K Buy
+8,400
New +$64.2K ﹤0.01% 4306
2024
Q3
– Sell
-15,300
Closed -$102K – 5221
2024
Q2
$102K Buy
15,300
+13,900
+993% +$103K ﹤0.01% 4706
2024
Q1
$14.3K Buy
+1,400
New +$14.2K ﹤0.01% 4998
2022
Q4
– Sell
-3,200
Closed -$41K – 3146
2022
Q3
$41K Buy
+3,200
New +$47.2K ﹤0.01% 2629

Other funds holding ALT

Walleye Capital's ALT Position: Q3 2026 in Review

Walleye Capital reduced its Altimmune (ALT) stake by 100% in Q3 2026, selling an estimated $26.1K and leaving 2 shares worth $6. The position accounts for ﹤0.01% of the portfolio, ranked #5912.

Walleye Capital first reported a position in ALT in Q4 2021 and has held it in 14 quarters since. The position peaked at $1.58M in Q2 2022. 191 funds tracked by Wall St. Rank hold ALT as of Q3 2026.

  • Walleye Capital held 2 shares of Altimmune worth $6 as of Q3 2026.
  • Walleye Capital sold 8,497 Altimmune shares in Q3 2026, an estimated $26.1K.
  • Altimmune made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #5912 holding.
  • Walleye Capital first reported a position in Altimmune in Q4 2021 and has held it in 14 quarters since.
  • Walleye Capital's Altimmune position peaked at $1.58M in Q2 2022.
  • 191 funds tracked by Wall St. Rank held Altimmune as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.